Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2023 > Vol 4, №1 (2023) > Nitric oxide system in patients infected with Helicobacter pylori of different genotypes

Nitric oxide system in patients infected with Helicobacter pylori of different genotypes

Ekaterina Yu. Plotnikova , Lyubov A. Yaroshenko , Alyona O. Kutsaeva

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Introduction. Helicobacter pylori (Hp) is a class I biological carcinogen and the third leading cause of cancer death in the world, according to the World Health Organization. Hp infection represents a global public health problem in the 4.4 billion people living with Hp worldwide. The pathogenesis of helicobacteriosis is multifaceted: disorders in the nitric oxide (NO) system are involved in the development of the disease, along with other mechanisms. These aspects of the pathogenesis of helicobacteriosis are not well understood. In particular, such parts of the general problem as the significance of changes in the level of NO, its metabolites in the development of inflammatory and erosive-ulcer diseases of the gastroduodenal zone caused by different genotypes of Hp are not solved. After HP eradication, the content of NO synthase in the gastric mucosa decreases. However, the expression of the enzyme remains high in areas of intestinal metaplasia, which is considered the source of continued production of NO synthase even after Hp eradication. 
Aim. To investigate the level of nitrates/nitrites in the blood in patients infected with various genotypes of Hp. Materials and methods. 48 patients with inflammatory and erosive-ulcer diseases of the stomach and CPD infected with Hp were examined. R&D Systems kits were used to determine the level of nitrates/nitrites in the blood. For the diagnosis of helicobacteriosis, a classic respiratory test was used, as well as a polymerase chain reaction. CagA, VacA, BabA, IceA genotyping Hp was performed. Depending on gene detection, Hp strains were divided into 4 serotypes: type I (CagA+, VacA+)/Type Ia (CagA+, VacA-), type Ib (CagA-, VacA+), type II (Vac A-, CagA-). 
Discussion. Нр harboured the CagA gene in 34 patients (70.8% of cases), VacA gene in 40 patients (83.3%), BabA gene in 6 patients (12.5%), and IceA gene in 8 patients (16.7%). The distribution by Нр serotype showed that serotype I was found in 28 patients (58.3%), serotype Ia in 6 patients (12.5%), serotype Ib in 12 patients (25.0%), and serotype II in 2 patients (4.2%). In general, all surveyed patients had blood levels of nitrates/nitrites that were significantly increased to 54.7±2.4 μmol/L (compared to the levels of healthy individuals, p<0.05). The patients infected with the CagA-positive Нр strains had the highest blood levels of NO metabolites. 
Conclusions. In helicobacteriosis, the level of NO metabolites in the blood is increased, especially in patients infected with CagA+, IceA+ strains of Hp. This is the basis for the development of a differentiated treatment for inflammatory and erosive-ulcer diseases of the gastroduodenal zone associated with different strains of Hp. 
Keywords: Helicobacter pylori, Hp, NO synthase, CagA, VacA, BabA, IceA genotypes Hp, blood nitrate/nitrite level, Hp eradication

About the Author

Ekaterina Yu. Plotnikova 1 , Lyubov A. Yaroshenko 2 , Alyona O. Kutsaeva 3

1 Kemerovo State Medical University, Kemerovo, Russia

2 Gorky Donetsk National Medical University, Donetsk, Russia

3 Podgorbunsky Kuzbass Clinical Hospital of Emergency Medical Care, Kemerovo, Russia

References

1. World Health Organization, International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: schistosomes, liver lukes, and Helicobacter pylori. Vol 61 Lyon: IARC, 1994. First published: 3 March 1995. DOI: 10.1002/ ijc.2910600502 
2. Liu H, Chen YT, Wang R et al. Helicobacter pylori infection, atrophic gastritis, and pancreatic cancer risk: a meta-analysis of prospective epidemiologic studies. Medicine 2017; 96: e7811. DOI: 10.1097/MD. 0000000000007811 
3. Yoshida T, Kato J, Inoue I et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Int J Cancer 2014; 134: 1445–57. DOI: 10.1002/ijc.28470 
4. Chen XZ, Schöttker B, Castro FA et al. Association of helicobacter pylori infection and chronic atrophic gastritis with risk of colonic, pancreatic and gastric cancer: a ten-year follow-up of the ESTHER cohort study. Oncotarget 2016; 7: 17182–93. DOI: 10.18632/oncotarget.7946 
5. Song H, Held M, Sandin S et al. Increase in the prevalence of atrophic gastritis among adults age 35 to 44 years old in Northern Sweden between 1990 and 2009. Clin Gastroenterol Hepatol 2015; 13: 1592– 600. e1591. DOI: 10.1016/j.cgh.2015.04.001 
6. Kayali S, Manfredi M, Gaiani F et al. Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta BioMedica: Atenei Parmensis 2018; 89 (8-s): 72–6. DOI: 10.23750/abm. v89i8-S.7947 
7. Mladenova I, Durazzo M. Transmission of Helicobacter pylori. Minerva gastroenterologica e dietologica 2018; 64 (3): 251–54. DOI: 10.23736/s1121-421x.18.02480-7 
8. Hooi JKY, Lai WY, Ng WK et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153 (2): 420–29. DOI: 10.1053/j.gastro.2017.04.022 
9. Rokkas T, Pistiolas D, Sechopoulos P et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5 (12): 1413–7, 17.e1-2. DOI: 10.1016/j.cgh.2007.08.01 
10. Mungan Z, Pınarbası Şimşek B. Gastroesophageal reflux disease and the relationship with Helicobacter pylori. Turkish J Gastroenterol 2017; 28 (Suppl. 1): S61–s67. DOI: 10.5152/tjg.2017.16 
11. de Martel C, Georges D, Bray F et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Global Health 2020; 8 (2): e180–e90. DOI: 10.1016/s2214- 109x(19)30488-7 
12. Zuo Y, Jing Z, Bie M et al. Association between Helicobacter pylori infection and the risk of colorectal cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2020; 99 (37): e21832. DOI: 10.1097/md.0000000000021832 
13. Poorolajal J, Moradi L, Mohammadi Y et al. Risk factors for stomach cancer: a systematic review and meta-analysis. Epidemiol Health 2020; 42: e2020004. DOI: 10.4178/epih.e2020004 
14. Ford AC, Gurusamy KS, Delaney B et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev 2016; 4 (4): Cd003840. DOI: 10.1002/14651858. CD003840.pub5 
15. Mansori K, Moradi Y, Naderpour S et al. Helicobacter pylori infection as a risk factor for diabetes: a meta-analysis of case-control studies. BMC Gastroenterology 2020; 20 (1): 77. DOI: 10.1186/s12876-020- 01223-0 
16. Fang Y, Fan C, Xie H. Effect of Helicobacter pylori infection on the risk of acute coronary syndrome: A systematic review and metaanalysis. Medicine (Baltimore) 2019; 98 (50): e18348. DOI: 10.1097/md.0000000000018348 
17. Wei X, Zhao HQ, Ma C et al. The association between chronic periodontitis and oral Helicobacter pylori: A meta-analysis. PLoS One 2019; 14 (12): e0225247. DOI: 10.1371/journal.pone.0225247 
18. Liu R, Liu Q, He Y et al. Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis. Medicine (Baltimore) 2019; 98 (44): e17781. DOI: 10.1097/md.0000000000017781 
19. Chen Q, Zhou X, Tan W et al. Association between Helicobacter pylori infection and Sjögren syndrome: A meta-analysis. Medicine (Baltimore) 2018; 97 (49): e13528. DOI: 10.1097/md.0000000000013528 
20. Li X, Peng L, Shen X et al. The Association between Infertility and Helicobacter pylori Infection: a Meta-Analysis of Case-control Studies. Clinical Laboratory 2018; 64 (9): 1385–93. DOI: 10.7754/Clin.Lab. 2018.180206 
21. Yong WC, Upala S, Sanguankeo A. Helicobacter pylori infection in systemic sclerosis: a systematic review and meta-analysis of observational studies. Clin Exp Rheumatol 2018; 36 Suppl. 113 (4): 168–74. 
22. Bellos I, Daskalakis G, Pergialiotis V. Helicobacter pylori infection increases the risk of developing preeclampsia: A meta-analysis of observational studies. Int J Clin Pract 2018; 72 (2). DOI: 10.1111/ijcp.13064 
23. Poorolajal J, Moradi L, Mohammadi Y et al. Risk factors for stomach cancer: a systematic review and meta-analysis. Epidem Health 2020; 42: e2020004. DOI: 10.4178/epih.e2020004 
24. Исаков В.А., Домарадский И.В. Хеликобактериоз. М.: Медпрактика-М, 2003. [Isakov V.A., Domaradskij I.V. Helikobakterioz. Moscow: Medpraktika-M, 2003 (in Russian).] 
25. Голиков П.П. Оксид азота в клинике неотложных заболеваний. М.: Медпрактика-М, 2004. [Golikov P.P. Oksid azota v klinike neotlozhnyh zabolevanij. Moscow: Medpraktika-M, 2004 (in Russian).] 
26. Gobert AP, McGee DJ, Akhtar M et al. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. Proc Natl Acad Sci USA 2001; 98 (24): 13844–9. DOI: 10.1073/pnas.241443798 
27. von Bothmer C, Edebo A, Lonroth H et al. Helicobacter pylori infection inhibits antral mucosal nitric oxide production in humans. Scand J Gastroenterol 2002; 37 (4): 404–8. DOI: 10.1080/003655202317316024 
28. Chautrand T, Souak D, Chevalier S, Duclairoir-Poc C. Gram-Negative Bacterial Envelope Homeostasis under Oxidative and Nitrosative Stress. Microorganisms 2022; 10 (5): 924. DOI: 10.3390/microorganisms10050924 
29. Park AM, Nagata K, Sato EF et al. Mechanism of strong resistance of Helicobacter pylori respiration to nitric oxide. Arch Biochem Biophys 2003; 411 (1): 129–35. 
30. Rieder G, Hofmann JA, Hatz RA et al. Up-regulation of inducible nitric oxide synthase in Helicobacter pylori-associated gastritis may represent an increased risk factor to develop gastric carcinoma of the intestinal type. Int J Med Microbiol 2003; 293 (6): 403–12. DOI: 10.1078/1438-4221-00280 
31. Li CQ, Pignatelli B, Ohshima H. Coexpression of interleukin-8 and inducible nitric oxide synthase in gastric mucosa infected with cagA+ Helicobacter pylori. Dig Dis Sci 2000; 45 (1): 55–62. DOI: 10.1023/a:1005453125433 
32. Mintz J, Vedenko A, Rosete O et al. Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics. Vaccines (Basel) 2021; 9 (2): 94. DOI: 10.3390/vaccines9020094

For citation:Plotnikova E.Yu., Yaroshenko L.A., Kutsaeva A.O. Nitric oxide system in patients infected with Helicobacter pylori of different genotypes. Clinical review for general practice. 2023; 4 (1): 49–52. DOI: 10.47407/kr2023.4.1.00189


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru